AddLife (STO:ALIF B) Third Quarter 2024 Results
Key Financial Results
- Revenue: kr2.34b (up 1.1% from 3Q 2023).
- Net income: kr24.0m (down 4.0% from 3Q 2023).
- Profit margin: 1.0% (in line with 3Q 2023).
- EPS: kr0.20 (down from kr0.20 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
AddLife Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) also missed analyst estimates by 50%.
Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Life Sciences industry in Sweden.
Performance of the Swedish Life Sciences industry.
The company's shares are down 12% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for AddLife you should be aware of, and 1 of them makes us a bit uncomfortable.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:ALIF B
AddLife
Provides equipment, consumables, and reagents primarily to healthcare sector, research, colleges, and universities, as well as the food and pharmaceutical industries.
Reasonable growth potential and slightly overvalued.
